UCL hosts leading UK academic rheumatology units. We work on a range of autoimmune rheumatic connective tissue diseases. Our teams work across two campuses, taking advantage of new academic research laboratories at both sites and the closely aligned clinical facilities at 911±¬ÁÏÍøH in Bloomsbury and the Royal Free Hospital in Hampstead.
Rheumatology (Bloomsbury)
We explore diseases such as systemic lupus erythematosus (SLE), antiphospholipid syndrome and rheumatoid arthritis. These are characterised by systemic or localised chronic inflammation, potentially leading to irreversible damage. Our work also encompasses the study of pathogenic B cells in juvenile and adolescent rheumatic disease, autoantibodies, and how the role of sex/gender and metabolic / cardiovascular risk impact upon disease severity and progression. We are identified as a Lupus Centre of Excellence by Lupus UK, the main SLE patients' charity, and as a Centre for Adolescent Rheumatology by Versus Arthritis, the largest rheumatology charity in the UK.
We explore diseases such as scleroderma and organ-based manifestations such as blood vessel disease, lung fibrosis and pulmonary hypertension. These are characterised by inflammation, tissue damage and remodelling or excessive repair, often leading to destruction and degeneration of the target organ and replacement with scar or fibrotic tissue. We are identified as a national centre of excellence for the study and management of Scleroderma. We link to one of eight National Referral Centres for pulmonary hypertension and have established an international reputation in the subspecialty field of connective tissue disease associated pulmonary arterial hypertension.
The FLARRE Consortium unites basic, biomedical and clinical scientists from across 911±¬ÁÏÍøith industrial and international collaborators. Our aim is to highlight research in inflammation, tissue remodelling, scarring and fibrosis, to develop a UCL cluster of expertise and research excellence. Through investigation, invention and collaboration with industry, we aim to increase the understanding of these diseases and translate our findings into patient benefit.
Oppong AE, Coelewij L, Robertson G, Martin-Gutierrez L ... Jury ECÌý(2024).Ìý. iScience. 2024 Feb 15;27(3): 109225.
Cope A, Jasenecova M, Vasconcelos JC, Filer A ... Ciurtin C, et al (2024). . The Lancet.
Papaioannou I, Dritsoula A, Kang P, Baliga RS, Trinder SL, Cook E, Shiwen X, Hobbs AJ, Denton CP, Abraham DJ, Ponticos M (2024). . JCI Insight. 2024 Apr 23;9(10): e164191.